Abstract: Purpose: Psoriasis patients have high risk of atherosclerosis, characterized by endothelial dysfunction. We
aimed to study the association of the endothelial activation biomarkers monocyte chemoattractant protein
1 (MCP-1), soluble (s) E-selectin and P-selectin with disease activity and severity in psoriasis patients
treated with anti-TNF-a therapy. Also, to evaluate the relationship of metabolic syndrome features with
these biomarkers and the effect of anti-TNF-a therapy on these molecules.
Methods: Twenty-nine consecutive non-diabetic patients with moderate-to-severe psoriasis who underwent
6 months of anti-TNF-a-adalimumab therapy were studied. Metabolic and clinical evaluation was performed
prior to anti-TNF-a treatment (time 0) and 6 months later. MCP-1, sE-selectin and sP-selectin serum
levels were determined by ELISA.
Results: Dyslipidemic and obese patients showed higher MCP-1 levels at month 6 from the onset of
anti-TNF-a therapy (p¼.05 and .01, respectively). sE-selectin positively correlated with pro-inflammatory
molecules such as asymmetric dimethylarginine, sP-selectin and resistin at baseline and month 6 (p<.05).
sE-selectin levels significantly reduced after 6 months of therapy (p¼.0006).
Conclusions: Metabolic syndrome features are associated with endothelial activation in patients with
moderate-to-severe psoriasis. Adalimumab therapy led to a reduction in sE-selectin levels, supporting the
beneficial effect of anti-TNF-a therapy on mechanisms associated with the development of atherosclerosis